financetom
Business
financetom
/
Business
/
Former US Secretary Kerry calls for new trade rules, cooperation with China on climate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Former US Secretary Kerry calls for new trade rules, cooperation with China on climate
Sep 22, 2024 12:19 AM

HOUSTON (Reuters) - Former U.S. Secretary of State John Kerry on Wednesday urged a new look at global trade rules, calling the existing mediator of trade disputes, the World Trade Organization, "neutered."

Kerry, who stepped down as President Joe Biden's climate envoy earlier this year, also urged cooperation with China on climate in wide ranging comments on trade, tariffs and the energy transition from fossil fuels at the Gastech energy conference in Houston.

"We need an understanding among nations, which China and the U.S. could help lead, about fair processes within the trading structure of the world," said Kerry.

The Geneva-based WTO "has become somewhat neutered, I think it is fair to say," he added.

The former Biden campaign worker took issue with the rising use of tariffs on Chinese imports that Biden and former President Donald Trump have relied on to rebuild U.S. industry and encourage clean energy businesses such as solar panels, batteries and electric cars.

"I'm not big on tariffs at all. I think historically tariffs have proven to be very problematic for the marketplace and countries," Kerry said. "I'm more believing in creating incentives for the things you want to do."

Nations need to find a way to cooperate with China on climate even as trade disputes grow, he said.

"I advocate working with China on climate because China is 30% of all emissions on the planet and is now the biggest producer of some of these (energy transition) technologies."

U.S. lawmakers and regulators need to address permitting for clean energy projects, which have been stalled by lengthy review periods and repeated challenges.

"We have some blockages - political and regulatory - and one of them is the permitting, you cannot take 10 years to permit this stuff, we don't have that kind of time," he said. "Nobody else is going to sit around and wait for us to get our act together."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cadence Bank Q3 Adjusted Earnings, Revenue Rise
Cadence Bank Q3 Adjusted Earnings, Revenue Rise
Oct 20, 2025
04:52 PM EDT, 10/20/2025 (MT Newswires) -- Cadence Bank ( CADE ) reported Q3 adjusted earnings late Monday of $0.81 per diluted share, up from $0.73 a year earlier. Analysts polled by FactSet expected $0.77. Revenue, expressed as the sum of net interest income and total noninterest income, for the quarter ended Sept. 30 rose to $517.2 million from $447.4...
General Dynamics gets $3.5 billion scout vehicle contract from Germany
General Dynamics gets $3.5 billion scout vehicle contract from Germany
Oct 20, 2025
(Reuters) -General Dynamics ( GD ) said on Monday that its Europe unit has secured a contract for about 3 billion euros ($3.50 billion) to deliver next-generation reconnaissance vehicle for the German Army Reconnaissance Corps. The contract was commissioned to General Dynamics European Land Systems by the Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support (BAAINBw). The company...
Teva, Prestige Biopharma Sign Deal to Commercialize Tuznue Cancer Biosimilar in Europe
Teva, Prestige Biopharma Sign Deal to Commercialize Tuznue Cancer Biosimilar in Europe
Oct 20, 2025
04:51 PM EDT, 10/20/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Monday it entered into a licensing and supply agreement with Prestige Biopharma to market Tuznue, a biosimilar to Herceptin, also known as trastuzumab, in most European markets. Tuznue, approved by the European Commission in September 2024, is indicated for HER2-positive breast and metastatic gastric cancers, Teva...
Columbia Financial Q3 Earnings, Revenue Rise
Columbia Financial Q3 Earnings, Revenue Rise
Oct 20, 2025
04:53 PM EDT, 10/20/2025 (MT Newswires) -- Columbia Financial ( CLBK ) reported Q3 earnings late Monday of $0.15 per diluted share, up from $0.06 a year earlier. Two analysts polled by FactSet expected $0.13. Revenue, expressed as the sum of net interest income and total noninterest income, for the quarter ended Sept. 30 was $67.3 million, up from $54.3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved